irasia.com - Investor Relations Asia Pacific
HOME

CSPC Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)

Announcements & Notices       


Please download the latest "Acrobat Reader" to view the PDF.

  • 2023-December-20
  • ELECTIONS OF MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS (in PDF)
  • 2023-December-18
  • VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR IRINOTECAN LIPOSOME INJECTION TO U.S. FDA (in PDF)
  • 2023-December-12
  • VOLUNTARY ANNOUNCEMENT - DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE ORALLY DISINTEGRATING TABLETS OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-December-1
  • VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA (in PDF)
  • 2023-November-30
  • VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-November-30
  • QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 (in PDF)
  • 2023-November-29
  • POLL RESULTS OF THE FURTHER ADJOURNED EGM HELD ON 29 NOVEMBER 2023 (in PDF)
  • 2023-November-27
  • VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-November-20
  • DATE OF BOARD MEETING (in PDF)
  • 2023-November-17
  • VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR TREATMENT OF ACUTE ISCHEMIC STROKE OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (in PDF)
  • 2023-November-13
  • NOTICE OF FURTHER ADJOURNED EGM (in PDF)
  • 2023-November-10
  • FURTHER ADJOURNMENT OF EGM (in PDF)
  • 2023-November-6
  • VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA (in PDF)
  • 2023-November-3
  • ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING NOTICE OF ADJOURNED EXTRAORDINARY GENERAL MEETING (in PDF)
  • 2023-November-3
  • VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-November-1
  • VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-October-30
  • VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-October-25
  • VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (in PDF)
  • 2023-October-24
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 (in PDF)
  • 2023-October-9
  • NOTICE OF EXTRAORDINARY GENERAL MEETING (in PDF)
  • 2023-October-9
  • DESPATCH OF CIRCULAR IN RELATION TO (1) GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND (2) APPLICATION FOR WHITEWASH WAIVER (in PDF)
  • 2023-September-22
  • DELAY IN DESPATCH OF CIRCULAR (in PDF)
  • 2023-September-15
  • VOLUNTARY ANNOUNCEMENT - IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-September-12
  • APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER (in PDF)
  • 2023-September-6
  • (REVISED) VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA (in PDF)
  • 2023-September-6
  • VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA (in PDF)
  • 2023-September-4
  • GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND APPLICATION FOR WHITEWASH WAIVER (in PDF)
  • 2023-August-29
  • VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-August-28
  • 2023 INTERIM DIVIDEND (in PDF)
  • 2023-August-24
  • VOLUNTARY ANNOUNCEMENT - SACUBITRIL VALSARTAN SODIUM TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-August-23
  • 2023 INTERIM DIVIDEND (in PDF)
  • 2023-August-23
  • 2023 INTERIM RESULTS (in PDF)
  • 2023-August-21
  • VOLUNTARY ANNOUNCEMENT - STRATEGIC COLLABORATION AGREEMENTS IN THE FIELD OF ARTIFICIAL INTELLIGENCE (AI) IN INNOVATIVE DRUG RESEARCH AND DEVELOPMENT (in PDF)
  • 2023-August-17
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2023 (in PDF)
  • 2023-August-17
  • VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. (in PDF)
  • 2023-August-11
  • DATE OF BOARD MEETING (in PDF)
  • 2023-July-4
  • VOLUNTARY ANNOUNCEMENT - DESVENLAFAXINE SUCCINATE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-July-3
  • VOLUNTARY ANNOUNCEMENT - RABEPRAZOLE SODIUM ENTERIC-COATED TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-June-29
  • VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION OF BATOCLIMAB (HBM9161) ACCEPTED BY THE NMPA (in PDF)
  • 2023-June-29
  • VOLUNTARY ANNOUNCEMENT - STRATEGIC PARTNERSHIP WITH PFIZER TO LAUNCH LOCAL BRAND OF ORAL ANTIVIRAL TREATMENT FOR COVID-19 IN CHINA (in PDF)
  • 2023-June-26
  • VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF OMALIZUMAB FOR INJECTION (in PDF)
  • 2023-June-26
  • VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-June-26
  • VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA (in PDF)
  • 2023-June-23
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2023-June-21
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2023-June-19
  • VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME (in PDF)
  • 2023-June-14
  • VOLUNTARY ANNOUNCEMENT - PALIPERIDONE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-June-14
  • VOLUNTARY ANNOUNCEMENT - MIRABEGRON EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-June-12
  • VOLUNTARY ANNOUNCEMENT - SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-June-12
  • VOLUNTARY ANNOUNCEMENT - CPO301 WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA (in PDF)
  • 2023-June-8
  • VOLUNTARY ANNOUNCEMENT - CPO301 OBTAINS CLINICAL TRIAL APPROVAL IN CANADA (in PDF)
  • 2023-May-31
  • POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 31 MAY 2023 (in PDF)
  • 2023-May-30
  • VOLUNTARY ANNOUNCEMENT - CLINICAL DATA OF ALMB-0168 FOR THE TREATMENT OF OSTEOSARCOMA TO BE PRESENTED AT THE 2023 ASCO ANNUAL MEETING (in PDF)
  • 2023-May-30
  • GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY (in PDF)
  • 2023-May-25
  • QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2023 (in PDF)
  • 2023-May-15
  • DATE OF BOARD MEETING (in PDF)
  • 2023-April-26
  • VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS (in PDF)
  • 2023-April-26
  • NOTICE OF ANNUAL GENERAL MEETING (in PDF)
  • 2023-April-25
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2023 (in PDF)
  • 2023-April-20
  • VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-April-2
  • VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE CPO301 OBTAINS CLINIAL TRIAL APPROVAL IN THE U.S. (in PDF)
  • 2023-March-27
  • VOLUNTARY ANNOUNCEMENT - "APREMILAST TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2023-March-22
  • CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER (in PDF)
  • 2023-March-22
  • ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022 (in PDF)
  • 2023-March-22
  • VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA (in PDF)
  • 2023-March-16
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2022 (in PDF)
  • 2023-March-10
  • VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION (in PDF)
  • 2023-March-10
  • DATE OF BOARD MEETING (in PDF)
  • 2023-March-2
  • VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA (in PDF)
  • 2023-February-23
  • REMUNERATION COMMITTEE - TERMS OF REFERENCE (in PDF)
  • 2023-February-23
  • NOMINATION COMMITTEE - TERMS OF REFERENCE (in PDF)
  • 2023-February-16
  • VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA (in PDF)
  • 2023-February-13
  • VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6002 WITH CORBUS PHARMACEUTICALS (in PDF)
  • 2023-January-19
  • VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-January-9
  • VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-January-5
  • VOLUNTARY ANNOUNCEMENT - MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2023-January-4
  • VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PRMT5 INHIBITOR SYH2045 OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2024
  • 2024 Announcements & Notices
  • 2022
  • 2022 Announcements & Notices
  • 2021
  • 2021 Announcements & Notices
  • 2020
  • 2020 Announcements & Notices
  • 2019
  • 2019 Announcements & Notices
  • 2018
  • 2018 Announcements & Notices
  • 2017
  • 2017 Announcements & Notices
  • 2016
  • 2016 Announcements & Notices
  • 2015
  • 2015 Announcements & Notices
  • 2014
  • 2014 Announcements & Notices
  • 2013
  • 2013 Announcements & Notices
  • 2012
  • 2012 Announcements & Notices
  • 2011
  • 2011 Announcements & Notices
  • 2010
  • 2010 Announcements & Notices
  • 2009
  • 2009 Announcements & Notices
  • 2008
  • 2008 Announcements & Notices
  • 2007
  • 2007 Announcements & Notices
  • 2006
  • 2006 Announcements & Notices


  • Company's Index
  • irasia.com

  • About irasia.com   |   Terms of Use   |   Privacy Policy Statement   |   Disclaimer
    © Copyright 1996-2024 irasia.com Ltd. All rights reserved.
    DISCLAIMER:
    irasia.com Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd. be liable for damages resulting from the use of the information provided on this website.
    Cookie Policy

    This website uses cookies. Please refer to our Cookie Notice and Privacy Notice for further information. By continuing to use this website, you agree to our use of cookies.

    Close